Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 9/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CTSG | P08311 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11171419 | 1.00 | CAPN1 (0.51) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL11172654 | 0.84 | CAPN1 (0.70) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL6070617 | 0.83 | CTSL (0.46) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL2387693 | 0.81 | TSHR (0.55) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL5317413 | 0.81 | TSHR (0.55) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL2387697 | 0.81 | TSHR (0.55) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL2387688 | 0.81 | TSHR (0.55) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL11545787 | 0.81 | TSHR (0.55) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL7047730 | 0.80 | CAPN1 (0.48) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL7047733 | 0.80 | CAPN1 (0.48) | CAPN1CTSLCTSBLMNACTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227806-A1 | Novel Drugs for Dementia | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227806-A1 | Novel Drugs for Dementia | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2008-09-18 | — | — | US | disclosed |
| WO-2007038772-A1 | NOVEL DRUGS FOR DEMENTIA | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227806-A1 | Novel Drugs for Dementia | CTSS, PRSS1, CBS | CAPN1 273/4885CTSL 37/4885CTSB 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.